Hyperprolactinemia and bone metabolism disorders due to antipsychotics in patients with schizophrenia

KARAKUS G., Tamam L., ZENGIN M.

ANADOLU PSIKIYATRI DERGISI-ANATOLIAN JOURNAL OF PSYCHIATRY, cilt.10, sa.4, ss.336-342, 2009 (SCI-Expanded) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 10 Sayı: 4
  • Basım Tarihi: 2009
  • Dergi Adı: ANADOLU PSIKIYATRI DERGISI-ANATOLIAN JOURNAL OF PSYCHIATRY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.336-342
  • Anahtar Kelimeler: schizophrenia, hyperprolactinemia, bone metabolism disorder, PLASMA PROLACTIN LEVELS, MINERAL DENSITY, FEMALE-PATIENTS, RISPERIDONE, MEDICATION, OLANZAPINE, OSTEOPOROSIS, NEUROLEPTICS, HALOPERIDOL, PREVALENCE
  • Çukurova Üniversitesi Adresli: Evet

Özet

Schizophrenia has influenced approximately 1% of the general population. If the schizophrenia spectrum disorders (schizoid personality disorder, schizotypal personality disorder, schizoaffective disorder and paranoid disorder) have been included, this rate would increase to 5%. Psychiatric disorders, sun light deficiency, inadequate exercise, smoking and polidipsia are predisposing factors for decreased bone mineral density and disruption in bone metabolism of patients with schizophrenia and schizoaffective disorders. The effects of antipsychotic drugs on bone metabolism are closely associated with hyperprolactinemia and hypogonadal states. Although in this group of patients hyperprolactinemia is seen commonly, bone metabolism disorders are not investigated and not included among routine procedures. That way they are usually missed out of sight. Recently, interest on bone metabolism disorders increase. Patients with bone metabolism disorder should be acknowledged that they must add calcium and vitamin D supplements to diet; regularly lose weight, do exercise, avoid cigarette, caffeine and alcohol; benefit good enough of sunshine. Using antipsychotics with no effect on prolactine levels, hormone replacement therapy and biophosphonate supplement is recommended for the treatment of this situation. (Anatolian Journal of Psychiatry 2009; 10:336-342)